AUROPHARMA

Business overview Indian multinational pharma company headquartered in Hyderabad. Major business: generic drugs + APIs + global exports. Revenue & Profit growth FY25 revenue: ₹31,723 crore (≈10% growth). FY25 PAT: ₹3,485 crore (≈10% growth). Latest TTM revenue around ₹31,700+ crore. ➡️ Indicates stable mid-single digit growth pharma company. Balance sheet Cash: ₹8,892 crore Debt: ₹7,795 crore Net cash positive company. ➡️ Balance sheet is strong and low risk.